PRINCETON, NJ / ACCESSWIRE / December 21, / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company The Sonnet BioTherapeutics Holdings stock forecast for tomorrow is $ , which would represent a % loss compared to the current price. In the next week, the price of SONN is expected to decrease by % and hit $ As far as the long-term Sonnet BioTherapeutics Holdings stock forecast is concerned, here’s what our Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J. Stock split history for Sonnet BioTherapeutics Holdings since
Sonnet BioTherapeutics Holdings, Inc. (SONN) - Yahoo Finance
Company Profile. Headquartered in Princeton, NJ, Sonnet BioTherapeutics is a clinical stage biotechnology company with a proprietary platform for innovating biologic drugs of single- or bi-specific mechanisms. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds Sonnet Biotherapeutics Holdings Inc. SONN.O. Latest Trade. USD. % As of Jan 19, Values delayed up to 15 minutes. Today's Range. - 52 Week Range. - Latest SONN news. Feb 15 am ET Sonnet BioTherapeutics price target lowered to $30 from $75 at Chardan By TipRanks Feb 15 am ET Buy Recommendation for Sonnet BioTherapeutics: Clinical
Sonnet BioTherapeutics Holdings NasdaqCM:SONN Stock Report
Welcome to our dedicated news page for Sonnet BioTherapeutics Holdings (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet BioTherapeutics Holdings. Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI Real-time Price Updates for Sonnet Biotherapeutics Holdings Inc (SONN-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more On February 10, , the company closed a public offering for gross proceeds of $ million (net proceeds of $ million), issuing 11,, shares of common stock, pre-funded warrants to purchase 2,, shares of common stock, with an exercise of $ per share, and common warrants to purchase 27,, shares of common